Apple
AAPL
Taylor Morrison Home
TMHC
D.R. Horton
DHI
Petroleo Brasileiro SA Petrobras
PBR
Vale SA
VALE
US Stock MarketDetailed Quotes
PRTG Portage Biotech
- 4.710
- +0.170+3.74%
Close Mar 27 16:00 ET
- 9.740
- +5.030+106.79%
Post 19:59 ET
7.75MMarket Cap-0.07P/E (TTM)
4.758High4.400Low2.37MVolume4.400Open4.540Pre Close22.51MTurnover292.23%Turnover RatioLossP/E (Static)1.65MShares23.01052wk High5.54P/B3.81MFloat Cap2.08052wk Low--Dividend TTM809.82KShs Float899.526Historical High--Div YieldTTM7.89%Amplitude2.080Historical Low9.513Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Portage Biotech Stock Forum
Game-Changing Mesothelioma Treatment: New Drug Achieves 90% Tumor Reduction in Latest Study
Many profit takers. Think before you buy
📊⚡️📊
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
Portage Biotech Presents New Data For PORT-7 At 2025 European Lung Cancer Congress
Benzinga· 20 mins ago1min
Portage Biotech(PRTG.US)
Portage Biotech Inc. (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo Italiano Mesotelioma e Oncologia Ambientale, at the 2025 European Lung Cancer ...
No comment yet